Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects
Clinical Study to Assess the Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects: Randomized, Double-blind, Placebo-controlled, Cross-over Study With Different Dosages
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Esslingen am Neckar, Germany, 73728
- BioTeSys GmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Prediabetic subjects: Male and female subjects with prediabetic HbA1c values between 5.7% and 6.4% and/or fasting glucose ≥ 100 mg/dL and ≤ 125 mg/dL (in venous plasma) (twice confirmed at two independent days if HbA1c is < 5.7%) or Healthy normo-glycaemic subjects: fasting glucose <100 mg/dL and HbA1c is < 5.7%
- Age: 18-70 years
- Body mass index 19-35 kg/m2
- Current Non-smoker
- Signed informed consent form
- No changes in food habits or physical activity 3 months prior to screening and during the study
- If applicable, stable intake of chronic medication of at least 4 weeks
Main Exclusion Criteria:
- Subjects with diagnosed Type 2 Diabetes mellitus with medical treatment
- Presence of disease or drug(s) influencing digestion (incl. recent intake of antibiotics) and absorption of nutrients
- Intake of medications known to affect glucose tolerance, e.g., diabetic medication, SGLT-2 inhibitors, GLP-1 receptor agonists, steroids, protease inhibitors or antipsychotics
- Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the Investigator's opinion would impact patient safety
- Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e. alkaline phosphatase, ALT, AST >3 x ULN)
- Known inflammatory or malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis)
- Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs
- Intake of food supplements known to affect glucose tolerance, e.g., cinnamon capsules, conjugated linoleic acids
- Drug-, alcohol- and medication abuses
- Pregnant or breast-feeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Collagen hydrolysate dose 1
Source: porcine; standardized to 10 g provided as single dose.
Orally applied in flavoured water.
|
Single dose
|
|
Experimental: Collagen hydrolysate dose 2
Source: porcine; standardized to 5 g provided as single dose.
Orally applied in flavoured water.
|
Single dose
|
|
Placebo Comparator: Placebo
Flavoured water
|
Single dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose iAUC
Time Frame: 0-180 minutes postprandially
|
Area under the curve (AUC) calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-180minutes)
|
0-180 minutes postprandially
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose iAUC
Time Frame: 0-240 minutes postprandially
|
Area under the curve calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration: Glucose-iAUC(0-240minutes)
|
0-240 minutes postprandially
|
|
Glucose Cmax
Time Frame: 0-180 minutes postprandially
|
Maximum blood glucose concentration (Cmax)
|
0-180 minutes postprandially
|
|
Delta Cmax
Time Frame: 0-180 minutes postprandially
|
Maximum increase of blood glucose concentration
|
0-180 minutes postprandially
|
|
Tmax
Time Frame: 0-180 minutes postprandially
|
Time to reach maximum blood glucose concentration (Tmax)
|
0-180 minutes postprandially
|
|
T baseline
Time Frame: 0-240 minutes postprandially
|
First time to reach baseline again after increase or decrease in blood glucose
|
0-240 minutes postprandially
|
|
Matsuda-Index
Time Frame: 0-120 minutes postprandially
|
Determination of Insulin sensitivity
|
0-120 minutes postprandially
|
|
Glucose dip
Time Frame: 0-240 minutes postprandially
|
maximum dip below baseline and time point of glucose dip
|
0-240 minutes postprandially
|
|
Insulin iAUC
Time Frame: up to 0-240 minutes postprandially
|
Area under the curve calculated as the incremental area under the insulin curve
|
up to 0-240 minutes postprandially
|
|
GLP-1
Time Frame: 0-120 minutes postprandially
|
Incretin response (Glucagon-like Peptide-1)
|
0-120 minutes postprandially
|
|
Satiety assessment
Time Frame: 0-240 minutes postprandially
|
Visual analog scale (VAS) Scale (0: not at all 100: extremely)
|
0-240 minutes postprandially
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amino acids
Time Frame: 0-240 minutes postprandially
|
Concentration-time curve of amino acids in plasma together with small molecular weight peptides
|
0-240 minutes postprandially
|
|
Gastrointestinal hormones
Time Frame: 0-120 minutes postprandially
|
Peptid YY (PYY), Ghrelin, Cholecystokinin (CCK), Leptin, Glucose-dependent Insulinotropic Polypeptide (GIP)
|
0-120 minutes postprandially
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Nicoletta Virgilio, PhD, Rousselot BV
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BTS1984/23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.